Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):264-9. Epub 2006 Dec 20.

3.

Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Odom GL, Gregorevic P, Chamberlain JS.

Biochim Biophys Acta. 2007 Feb;1772(2):243-62. Epub 2006 Sep 26. Review.

4.

rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS.

Nat Med. 2006 Jul;12(7):787-9. Epub 2006 Jul 2.

6.

Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.

Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG.

Hum Mol Genet. 2005 Jul 15;14(14):1921-33. Epub 2005 May 25.

7.

Structural abnormalities at neuromuscular synapses lacking multiple syntrophin isoforms.

Adams ME, Kramarcy N, Fukuda T, Engel AG, Sealock R, Froehner SC.

J Neurosci. 2004 Nov 17;24(46):10302-9. Erratum in: J Neurosci. 2004 Dec 15;24(50):11481.

8.
9.

Novel mutations in three patients with LGMD2C with phenotypic differences.

Vermeer S, Verrips A, Willemsen MA, ter Laak HJ, Ginjaar IB, Hamel BC.

Pediatr Neurol. 2004 Apr;30(4):291-4.

PMID:
15087111
10.

Concerted regulation of skeletal muscle contractility by oxygen tension and endogenous nitric oxide.

Eu JP, Hare JM, Hess DT, Skaf M, Sun J, Cardenas-Navina I, Sun QA, Dewhirst M, Meissner G, Stamler JS.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15229-34. Epub 2003 Nov 26.

11.

Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal Nitric oxide synthase.

Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, Adams ME.

Circ Res. 2003 Mar 21;92(5):554-60. Epub 2003 Feb 13.

12.

Loss of sarcolemma nNOS in sarcoglycan-deficient muscle.

Crosbie RH, Barresi R, Campbell KP.

FASEB J. 2002 Nov;16(13):1786-91.

13.

Functional characteristics of dystrophic skeletal muscle: insights from animal models.

Watchko JF, O'Day TL, Hoffman EP.

J Appl Physiol (1985). 2002 Aug;93(2):407-17. Review.

14.

Alpha-sarcoglycan deficiency featuring exercise intolerance and myoglobinuria.

Mongini T, Doriguzzi C, Bosone I, Chiadò-Piat L, Hoffman EP, Palmucci L.

Neuropediatrics. 2002 Apr;33(2):109-11.

PMID:
12075495
15.

Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury.

Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV.

J Muscle Res Cell Motil. 2001;22(5):467-75.

PMID:
11964072
16.

A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.

Wehling M, Spencer MJ, Tidball JG.

J Cell Biol. 2001 Oct 1;155(1):123-31.

17.

A standardized method for the evaluation of respiratory muscle endurance in patients with Duchenne muscular dystrophy.

Matecki S, Topin N, Hayot M, Rivier F, Echenne B, Prefaut C, Ramonatxo M.

Neuromuscul Disord. 2001 Mar;11(2):171-7.

PMID:
11257474
18.

Nitric oxide modulates excitation-contraction coupling in the diaphragm.

Reid MB, Kobzik L, Bredt DS, Stamler JS.

Comp Biochem Physiol A Mol Integr Physiol. 1998 Jan;119(1):211-8.

PMID:
11253787
19.

Physiology of nitric oxide in skeletal muscle.

Stamler JS, Meissner G.

Physiol Rev. 2001 Jan;81(1):209-237. Review.

20.

Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.

Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG.

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13818-23.

Items per page

Supplemental Content

Write to the Help Desk